Form 4: Journey Medical Corp Director Pearce Receives 30,000 Restricted Stock Units

Director Michael Cooper Pearce of Journey Medical Corp was granted 30,000 restricted stock units on July 19, 2024, under the company's 2015 Stock Plan.

Summary

• On July 19, 2024, Michael Cooper Pearce, a director of Journey Medical Corp, received 30,000 restricted stock units.
• These units were granted under the Issuer's 2015 Stock Plan.
• The restricted stock units will vest over a three-year period.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate governance practice of granting equity compensation. It's a neutral event with a slightly positive implication for aligning director interests with shareholder value.

Positives

• The grant of restricted stock units aligns the director's interests with the long-term performance of the company.
• The vesting schedule encourages continued service and contribution from the director.

Future Outlook

The restricted stock units will vest over a three-year period, incentivizing the director's continued service and contribution to the company.

Industry Context

Grants of restricted stock units are a common practice in corporate governance to align the interests of directors and management with those of shareholders, incentivizing long-term value creation.

Comparison to Industry Standards

• Equity compensation for board members is a common practice across the pharmaceutical and medical device industries.
• Companies like Amgen, Pfizer, and Johnson & Johnson also utilize stock options and restricted stock units as part of their director compensation packages.
• The specific amount and vesting schedule can vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see it as a sign of confidence in the company's future.

Key Dates